Navigating the evolving landscape of pharmaceutical patient support requires staying ahead of emerging technologies and industry trends. In this illuminating conversation with Cathy Zaremba from Medisafe’s Marketing team, we dive into key...
Television networks have developed a dangerous dependency on pharmaceutical advertising dollars, creating a precarious financial ecosystem that few outside the industry fully comprehend. Drug makers poured nearly $3.73 billion into national TV...
Pharmaceutical giants are abandoning the United Kingdom, and it’s sending shockwaves through global healthcare markets. When industry leaders call a major market “uninvestable,” every executive needs to pay attention.The stark...
The pharmaceutical landscape in America is undergoing a transformation unlike anything we’ve seen before. When the revised Most Favored Nation (MFN) drug pricing policy dropped in May 2025, few anticipated the tidal wave of strategic responses...
A seismic shift is underway at the FDA that could fundamentally alter how drugs reach American patients. Recent reporting reveals the agency is dramatically scaling back its use of independent advisory committees—consulting external experts on just...
The pharmaceutical advertising landscape stands at a crossroads as bold new regulatory initiatives threaten to upend decades of established marketing practices. This week, the administration announced plans directing the FDA to reconsider the 30...
A seismic shift is underway in pharmaceutical marketing regulation. Yesterday, the FDA fired a warning shot heard across the industry, announcing a massive crackdown on what they’re calling misleading pharmaceutical advertising. With over...
A quick chat with Medisafe’s Ryan Janvion, Stacey Wasserman and Cathy Zaremba on what to expect at Fierce Pharma Week 2025. Industry leaders discuss how hyper-personalization sets true patient engagement apart from the buzzwords that saturate...
A seismic shift is underway in pharmaceutical manufacturing. The FDA’s newly unveiled Advanced Manufacturing Technologies Designation Program promises to accelerate reviews for facilities producing drugs and biologics on American...
Regulatory timelines are changing dramatically, and pharmaceutical companies must adapt or risk being left behind. The Biden administration’s pressure on the FDA is yielding concrete results – approval processes that once took 10-12...